News and Announcements
BlockGrain Launch Agricultural Token Sale Accepting XEM
- Published June 18, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- BlockGrain has launched their token sale, accepting XEM and bitcoin.
- Their pre-sale has raised more than $3.5m.
- BlockGrain is considering NEM as their private chain in the future following this sale.
BlockGrain has launched the first Agricultural Token Sale in Australia. BlockGrain is now accepting XEM and Bitcoin in their public sale after a successful presale that saw over $3.5m contributed by over 1000 individuals. All participants are treated equally with no discounts between private and public sales. There will be no bonuses offered, resulting in the tokens retaining their value once they hit the exchanges. NEM (XEM) is a peer-to-peer cryptocurrency, blockchain platform and BlockGrain is considering using NEM as their private chain following this initial public sale using XEM.
BlockGrain is a software that provides farmers with an opportunity to build their own supply chain with buyers directly. Taking XEM into their public sale is an opportunity to see how much support the NEM foundation and community will put into the BlockGrain project. There is a significant presence of NEW community in Asia, making the adoption by the BlockGrain community. The token sale is set to end on 24 June 2018. BlockGrain will then assess how they will proceed concerning adopting XEM.
About BlockGrain
First industry-wide platform to provide seamless integration between growers, grain brokers, buyers and logistics providers building the best automated software solution to solve the agricultural industry’s greatest supply chain issues.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
